A5017625568- Biosimilars and Bioanalytical Methods
- Biosensors and Analytical Detection
- Renal Transplantation Outcomes and Treatments
- Drug-Induced Adverse Reactions
- Drug-Induced Hepatotoxicity and Protection
- Monoclonal and Polyclonal Antibodies Research
- Advanced Proteomics Techniques and Applications
- CAR-T cell therapy research
Sanofi (Germany)
2023-2025
Rheumatoid arthritis (RA) is one of the most common autoimmune diseases affecting primarily joints. Despite successful therapies including antibodies against tumor necrosis factor (TNF) and interleukin-6 (IL-6) receptor, only 20 to 30% patients experience remission. We studied whether inhibiting both TNF IL-6 would result in improved efficacy. Using backtranslation from single-cell RNA sequencing (scRNA-seq) data individuals with RA, we hypothesized that act synergistically on...
Significance Statement There is no standardized desensitization regimen for kidney transplant candidates. CD38, expressed by plasma cells, could be targeted to deplete cells producing alloantibodies and donor-specific antibodies. Few studies case reports are available regarding the use of CD38 antibodies in patients awaiting transplant. This study shows that isatuximab, a CD38-targeting therapy, was well tolerated candidates, with durable decrease anti-HLA partial activity. The short...
The 18th Workshop on Recent Issues in Bioanalysis (18th WRIB) took place San Antonio, TX, USA May 6-10, 2024. Over 1100 professionals representing pharma/biotech companies, CROs, and multiple regulatory agencies convened to actively discuss the most current topics of interest bioanalysis. WRIB included 3 Main Workshops 7 Specialized that together spanned 1 week allow an exhaustive thorough coverage all major issues bioanalysis biomarkers, immunogenicity, gene therapy, cell therapy...